Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Finished Goods (2021 - 2025)

Mirum Pharmaceuticals has reported Finished Goods over the past 5 years, most recently at $3.5 million for Q4 2025.

  • Quarterly results put Finished Goods at $3.5 million for Q4 2025, up 7.06% from a year ago — trailing twelve months through Dec 2025 was $3.5 million (up 7.06% YoY), and the annual figure for FY2025 was $3.5 million, up 7.06%.
  • Finished Goods for Q4 2025 was $3.5 million at Mirum Pharmaceuticals, up from $2.8 million in the prior quarter.
  • Over the last five years, Finished Goods for MIRM hit a ceiling of $11.3 million in Q3 2023 and a floor of $87000.0 in Q4 2021.
  • Median Finished Goods over the past 5 years was $3.3 million (2024), compared with a mean of $3.5 million.
  • Biggest five-year swings in Finished Goods: skyrocketed 6200.0% in 2023 and later tumbled 65.22% in 2024.
  • Mirum Pharmaceuticals' Finished Goods stood at $87000.0 in 2021, then surged by 145.98% to $214000.0 in 2022, then soared by 4311.68% to $9.4 million in 2023, then tumbled by 65.22% to $3.3 million in 2024, then grew by 7.06% to $3.5 million in 2025.
  • The last three reported values for Finished Goods were $3.5 million (Q4 2025), $2.8 million (Q3 2025), and $3.7 million (Q2 2025) per Business Quant data.